Alison Brophy
YOU?
Author Swipe
View article: Evolution and Transmission of Cefiderocol-Resistant <i>Acinetobacter baumannii</i> During an Outbreak in the Burn Intensive Care Unit
Evolution and Transmission of Cefiderocol-Resistant <i>Acinetobacter baumannii</i> During an Outbreak in the Burn Intensive Care Unit Open
We report on 11 critically ill burn patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. Clinical success was achieved in 36% and complicated by treatment-emergent resistance and interpatient trans…
View article: Real‐world evaluation of the impact of two anti‐SARS‐CoV‐2 monoclonal antibody regimens on COVID‐19 hospitalizations in older adults
Real‐world evaluation of the impact of two anti‐SARS‐CoV‐2 monoclonal antibody regimens on COVID‐19 hospitalizations in older adults Open
Evidence from clinical trials suggest anti‐SARS‐CoV‐2 monoclonal antibodies (mABs) may reduce coronavirus disease 2019 (COVID‐19)‐related hospitalizations. The purpose of this study was to assess the real‐world impact of mAB administration…
View article: Evaluation of Hospitalized Patient Outcomes in COVID-19 Infection for Continued versus Discontinued Use of Preadmission Antiplatelet Regimen
Evaluation of Hospitalized Patient Outcomes in COVID-19 Infection for Continued versus Discontinued Use of Preadmission Antiplatelet Regimen Open
Objective In SARS-CoV-2 (COVID-19) infection, it is unclear if continuation of preadmission antiplatelet regimens upon hospitalization will improve hypercoagulability outcomes. Methods: This retrospective cohort study analyzed adult patien…
View article: Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital
Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital Open
Objectives: Andexanet alfa is the first approved antidote in the management of life-threatening bleeds in patients treated with Xa inhibitors. The ANNEXA-4 study was successful in reducing factor Xa levels during time of administration but…
View article: 186. Prescriber-Led Antibiotic Timeout Alert Responses: A Retrospective Multicenter Study
186. Prescriber-Led Antibiotic Timeout Alert Responses: A Retrospective Multicenter Study Open
Background An antibiotic time out is when a clinician is prompted to reevaluate antibiotic therapy for appropriateness after 48–72 hrs. The purpose of this study is to evaluate the impact of a prescriber-led electronic antibiotic timeout a…